CDC issues global dengue alert as Americas see renewed rise

Publicly available health advisories show that the United States Centers for Disease Control and Prevention has issued a global alert on dengue as record case numbers in the Americas persist, raising fresh concerns for travelers heading into the southern hemisphere summer and the Caribbean high season.

Record dengue burden and a new phase of the outbreak

According to a 2024 global dengue situation update from the World Health Organization, last year marked the highest number of dengue cases ever recorded worldwide, with more than 100 countries reporting transmission and the Region of the Americas accounting for over 90 percent of infections. Data compiled by the Pan American Health Organization indicates that the Americas registered more than 13 million dengue cases in 2024, three times the already record figure reported for 2023.

Regional surveillance bulletins for 2025 and 2026 show that overall case counts in the Americas eased after the 2024 peak but remained well above pre‑pandemic averages. An epidemiological update released by PAHO in February 2026 reported a 66 percent fall in cases and a 74 percent reduction in deaths compared with 2024, yet millions of infections were still recorded across Latin America and the Caribbean, highlighting that dengue has entered a period of sustained high transmission rather than a short, isolated surge.

The CDC’s Health Alert Network advisory, issued during the height of the 2024 outbreak, pointed to this broader pattern by warning that global dengue activity had increased sharply over the previous five years. The advisory noted that this trend was translating into higher numbers of travel‑associated infections detected in the United States, particularly among people returning from popular vacation destinations in the Caribbean, Central America, and South America.

Climate patterns and rapid urbanization in tropical and subtropical regions are widely cited in technical reports as major drivers of this shift. Warmer temperatures, irregular rainfall, and expanding urban settlements without adequate water management have created ideal conditions for Aedes mosquitoes, which spread dengue, chikungunya, Zika, and several other viruses.

Americas remain the epicenter as new serotypes circulate

PAHO situation reports for 2024 describe a region‑wide event affecting 47 countries and territories in the Americas, with simultaneous circulation of all four dengue virus serotypes. Brazil, Argentina, Peru, Paraguay, and several Caribbean nations recorded historic peaks in suspected and confirmed cases. National summaries from Argentina and Peru highlighted prolonged transmission seasons and high caseloads extending into areas that had reported few or no dengue outbreaks in previous decades.

In February 2025, PAHO issued an epidemiological alert on the growing circulation of the DENV‑3 serotype in several countries of the Americas. The alert warned that shifts in predominant serotypes can increase the risk of sizeable outbreaks, particularly in places where large portions of the population have little prior exposure to the newly circulating variant. Technical documentation accompanying the alert also noted emerging evidence that one widely used dengue vaccine provided lower protection against DENV‑3, especially in children without previous dengue infection, underscoring the need for careful use of immunization as a complementary tool rather than a stand‑alone solution.

By late 2025 and into 2026, updated PAHO data showed that while the absolute number of cases had dropped from the 2024 peak, both Central America and the Caribbean continued to experience recurrent waves of infections. Several countries reported pressure on hospital services during seasonal spikes, despite maintaining a relatively low regional case‑fatality rate. Publicly available regional assessments emphasize that improved clinical management, early detection of warning signs, and timely referral have been critical in keeping deaths comparatively limited in relation to the record number of infections.

For travelers, these patterns mean that destinations with long‑established dengue transmission as well as areas that only recently began reporting sustained outbreaks can present comparable levels of risk during peak mosquito seasons. Urban centers, resort zones, and smaller coastal towns have all featured prominently in national case maps over the past two years, reflecting how widely Aedes mosquitoes have adapted to human environments.

CDC alert outlines risks for US travelers and territories

The CDC’s 2024 Health Alert Network advisory on dengue highlighted two concurrent concerns for the United States. First, US territories in the Caribbean and Pacific, including Puerto Rico, the US Virgin Islands, and American Samoa, experienced elevated levels of local transmission. Second, travel‑associated infections among residents of the continental United States reached the highest levels recorded in recent surveillance, mirroring the surge across Latin America and the Caribbean.

Agency data compiled for the advisory showed that from January through late June 2024, countries in the Americas reported more than 9.7 million dengue cases, over twice the total reported for all of 2023. Publicly available summaries indicate that this explosion of regional activity contributed to an 80‑plus percent year‑on‑year increase in dengue diagnoses among US travelers that year, with imported cases identified in a wide range of states beyond the traditional hotspots of Florida, Texas, and Arizona.

The CDC alert described an increased likelihood that some imported infections would seed limited local transmission in parts of the southern United States where Aedes mosquitoes are established. State and local health departments in Florida and other Gulf Coast jurisdictions recorded clusters of locally acquired dengue in 2024 and 2025, most of them small but sufficient to prompt targeted vector control operations and neighborhood‑level public advisories.

Subsequent communications from federal and regional health agencies have framed dengue as an enduring seasonal hazard that is likely to recur in US territories and appear sporadically in southern states, particularly during warm, wet periods. For travelers, this means that dengue precautions are now listed alongside more familiar concerns such as foodborne illness and respiratory infections when planning trips within the Americas.

What the alert means for trip planning in the Americas

While travel restrictions are not in place and airports and cruise ports across the Americas continue to operate normally, the CDC dengue alert and PAHO situation updates carry practical implications for trip planning. Travelers are being urged through public information campaigns to check current dengue activity at their destination before departure and to factor seasonal mosquito patterns into decisions about timing and itinerary.

For example, PAHO data show that many parts of South America, including Brazil, Paraguay, and northern Argentina, see dengue transmission intensify during the austral summer from roughly December to May. In the Caribbean, higher case counts are often linked to the rainy season, which can vary by island but frequently extends from late spring through autumn. Although these patterns can shift from year to year, published surveillance bulletins recommend that visitors adopt enhanced preventive measures when traveling during wetter and hotter months.

Travel medicine clinics and online health resources advise that people with certain medical conditions, such as chronic heart or lung disease, diabetes, or previous severe dengue, discuss their plans with a healthcare provider well in advance. Some countries in the region have introduced dengue vaccination for specific age groups or high‑risk populations, but access, eligibility criteria, and product choice differ widely, and publicly available guidance stresses that vaccines do not replace the need for mosquito bite prevention even when they are offered.

Travel insurance policies increasingly list dengue and other arboviral infections among the events that can trigger medical coverage or trip interruption benefits, but the scope of protection varies. Travelers are encouraged in consumer advisories to review policy language closely, paying particular attention to emergency medical limits, evacuation provisions, and exclusions related to known outbreaks or government advisories.

Practical steps for travelers to reduce dengue risk

The core advice for travelers heading to dengue‑affected areas centers on avoiding mosquito bites. Health agencies recommend using insect repellents registered with national regulators that contain ingredients such as DEET, picaridin, or IR3535, and applying them according to label instructions. Long‑sleeved shirts, long trousers, and socks in light colors can provide a physical barrier, particularly during the early morning and late afternoon hours when Aedes mosquitoes are most active.

Accommodation choice can significantly influence exposure. Public health guidance emphasizes selecting rooms with effective air conditioning and intact window and door screens where possible. In more rustic settings, especially in parts of the Amazon basin and rural Central America, travelers are encouraged to use bed nets treated with insecticide and to check for standing water in and around lodging areas, since buckets, plant pots, and even small containers can serve as mosquito breeding sites.

For urban trips, regional campaigns highlight that dengue transmission can be intense in city neighborhoods, not just in jungle or coastal environments. Visitors are advised to maintain protection whenever they are outdoors, including on hotel balconies, in open‑air restaurants, and while using rooftop pools or courtyards. Carrying repellent during day trips and reapplying it after swimming or heavy sweating is also recommended in official prevention materials.

Finally, travelers are encouraged to familiarize themselves with early symptoms such as sudden high fever, intense headache, pain behind the eyes, joint and muscle pain, and rash. Publicly available clinical guidance stresses that anyone who develops these signs during or after a trip to a dengue‑affected area should seek prompt medical evaluation and share recent travel details with their provider. Awareness of the CDC alert and the ongoing elevated dengue activity in the Americas can help clinicians and travelers alike recognize potential infections quickly and reduce the risk of severe disease.